The President & CEO of NPS Pharmaceuticals predicts tremendous growth for the pharmaceutical industry in the coming years as new cures and treatments are developed.
Francois Nader, MD, has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharma since 2008. During his tenure, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide.
Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS Pharma in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee. Dr. Nader is the immediate past chair of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry. He is also a Board member of the Biotechnology Industry Organization (BIO), the New Jersey Chamber of Commerce, Trevena, Inc., Clementia Pharmaceuticals, Inc. and Acceleron Pharma Inc. In 2013, Dr. Nader was recognized as the Ernst and Young National Life Science Entrepreneur of the Year.